Search for a trial

Tailoring neoadjuvant therapy in hormone receptor positive, HER2 negative, luminal breast cancer.

Primary objective:• Determine if ribociclib plus letrozole gives a >=100% improvement in complete cell cycle arrest (CCCA; defined as Ki67 IHC <1%) as compared to chemotherapy in the surgical specimen*.Secondary objective• Study the…

The ENDURRANCE-1 Study. ;Exploring durable remission with rituximab in ANCA associated vasculitis

This study has been transitioned to CTIS with ID 2023-507868-39-00 check the CTIS register for the current data. In this randomized study the primary objective is to demonstrate a clinical significant reduction of RTX retreatments in AAV patients…

Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) an international randomized phase III trial

This study has been transitioned to CTIS with ID 2024-516196-32-00 check the CTIS register for the current data. To investigate whether (neo)adjuvant systemic treatment of intensified alkylating chemotherapy with peripheral stem cell rescue (mini-…